NI201500176A - Derivados de prodroga de triazolpiridinas sustituidas - Google Patents

Derivados de prodroga de triazolpiridinas sustituidas

Info

Publication number
NI201500176A
NI201500176A NI201500176A NI201500176A NI201500176A NI 201500176 A NI201500176 A NI 201500176A NI 201500176 A NI201500176 A NI 201500176A NI 201500176 A NI201500176 A NI 201500176A NI 201500176 A NI201500176 A NI 201500176A
Authority
NI
Nicaragua
Prior art keywords
derivatives
triazolpyridines
prodrog
substituted
mps
Prior art date
Application number
NI201500176A
Other languages
English (en)
Inventor
Schulze Volker
Lerchen Hans-Georg
Bierer Donald
Margret Wengner Antje
Siemeister Gerhard
Lienau Philip
Krenz Ursula
Kosemund Dirk
Stöckigt Detlef
Brüning Michael
Lücking Ulrich
Terebesi Iidikó
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NI201500176A publication Critical patent/NI201500176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a derivados de prodroga de inhibidores de la quinasa Mps-1 de fórmula (I), procesos para su preparación y su uso en el tratamiento y/o la profilaxis de enfermedades.
NI201500176A 2013-06-11 2015-12-11 Derivados de prodroga de triazolpiridinas sustituidas NI201500176A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11

Publications (1)

Publication Number Publication Date
NI201500176A true NI201500176A (es) 2016-01-06

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500176A NI201500176A (es) 2013-06-11 2015-12-11 Derivados de prodroga de triazolpiridinas sustituidas

Country Status (35)

Country Link
US (1) US9586958B2 (es)
EP (1) EP3008062B1 (es)
JP (1) JP2016526534A (es)
KR (1) KR20160019492A (es)
CN (1) CN105377848A (es)
AP (1) AP2015008898A0 (es)
AR (1) AR096585A1 (es)
AU (1) AU2014280356A1 (es)
CA (1) CA2914745A1 (es)
CL (1) CL2015003605A1 (es)
CR (1) CR20150659A (es)
CU (1) CU20150176A7 (es)
DK (1) DK3008062T3 (es)
DO (1) DOP2015000299A (es)
EA (1) EA201600002A1 (es)
ES (1) ES2626790T3 (es)
HK (1) HK1221955A1 (es)
HR (1) HRP20170717T1 (es)
HU (1) HUE033131T2 (es)
IL (1) IL242847A0 (es)
LT (1) LT3008062T (es)
MA (1) MA38654B1 (es)
MX (1) MX2015017119A (es)
NI (1) NI201500176A (es)
PE (1) PE20160156A1 (es)
PH (1) PH12015502746A1 (es)
PL (1) PL3008062T3 (es)
PT (1) PT3008062T (es)
RS (1) RS56034B1 (es)
SG (1) SG11201509858QA (es)
SI (1) SI3008062T1 (es)
TN (1) TN2015000545A1 (es)
UY (1) UY35610A (es)
WO (1) WO2014198647A2 (es)
ZA (1) ZA201508868B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
PL3283642T3 (pl) 2015-04-17 2024-04-22 Crossfire Oncology Holding B.V. Biomarkery prognostyczne dla chemioterapii inhibitorem TTK
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
IL133007A (en) 1997-05-28 2005-06-19 Aventis Pharma Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
WO2005030121A2 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2057158B8 (en) 2006-08-30 2015-09-30 Cellzome Limited Triazole derivatives as kinase inhibitors
WO2008141065A1 (en) 2007-05-10 2008-11-20 Smithkline Beecham Corporation Quinoxaline derivatives as p13 kinase inhibitors
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
KR20100057650A (ko) 2007-08-23 2010-05-31 아스트라제네카 아베 증식성 질환의 치료를 위한 ｔｔｋ／ｍｐｓ１의 억제제로서 ２-아닐리노푸린-８-온
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
ES2474147T3 (es) 2008-05-30 2014-07-08 Amgen, Inc Inhibidores de PI3 cinasa
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EA201101188A1 (ru) 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
MX2012008259A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa.
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140120087A1 (en) * 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
BR112015000308A2 (pt) * 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
US20160264568A1 (en) * 2013-06-07 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
WO2014198594A1 (en) * 2013-06-10 2014-12-18 Bayer Pharma Aktiengesellschaft Novel compounds for the treatment of cancer
CA2914742A1 (en) * 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception

Also Published As

Publication number Publication date
UY35610A (es) 2015-01-30
HUE033131T2 (en) 2017-11-28
HK1221955A1 (zh) 2017-06-16
PL3008062T3 (pl) 2017-08-31
TN2015000545A1 (en) 2017-04-06
CR20150659A (es) 2016-01-29
EA201600002A1 (ru) 2016-06-30
PH12015502746A1 (en) 2016-03-21
ES2626790T3 (es) 2017-07-26
DK3008062T3 (en) 2017-06-12
EP3008062B1 (en) 2017-04-05
SG11201509858QA (en) 2015-12-30
WO2014198647A2 (en) 2014-12-18
CU20150176A7 (es) 2016-05-30
KR20160019492A (ko) 2016-02-19
MX2015017119A (es) 2016-04-06
US9586958B2 (en) 2017-03-07
SI3008062T1 (sl) 2017-06-30
MA38654B1 (fr) 2018-11-30
ZA201508868B (en) 2017-08-30
CL2015003605A1 (es) 2016-06-24
LT3008062T (lt) 2017-06-12
AP2015008898A0 (en) 2015-12-31
PT3008062T (pt) 2017-06-07
JP2016526534A (ja) 2016-09-05
CA2914745A1 (en) 2014-12-18
RS56034B1 (sr) 2017-09-29
PE20160156A1 (es) 2016-04-20
WO2014198647A3 (en) 2015-02-05
AR096585A1 (es) 2016-01-20
DOP2015000299A (es) 2016-03-15
AU2014280356A1 (en) 2015-12-24
US20160207915A1 (en) 2016-07-21
EP3008062A2 (en) 2016-04-20
HRP20170717T1 (hr) 2017-07-28
CN105377848A (zh) 2016-03-02
IL242847A0 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
DOP2015000274A (es) Compuestos químicos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20150633A (es) Derivados del bipirazol como inhibidores jak
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015010125A (es) Derivados de piridazinona-amidas.
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
NI201500096A (es) Compuesto químicos
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
CR20160133A (es) Derivados de fenilalanina sustituidos
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
PH12015502747A1 (en) Novel compounds for the treatment of cancer
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
AR095353A1 (es) Compuesto
NI201700072A (es) Compuestos para tratar el cáncer.